EyePoint initiated with an Outperform at Scotiabank

Scotiabank initiated coverage of EyePoint with an Outperform rating and $18 price target EyePoint has its own long-acting implant for wet AMD in pivotal development, Duravyu, which demonstrated positive efficacy and safety in a robust Phase 2 trial, notes the analyst, who sees “plenty of room in wAMD for multiple companies to have commercial success.” The firm suspects the long-acting implant market will be split among numerous products, as opposed to a winner-take-all dynamic, the analyst added.